Selecta Biosciences (SELB) Stock Analysis

What Selecta Biosciences does

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical firm dedicated to the research and development of innovative nanoparticle immunomodulatory medications aimed at treating and preventing various human ailments. The company's most advanced gene therapy initiative is SEL-302, currently in preclinical development to enhance therapeutic options for methylmalonic acidemia. Among its biologic therapies, SEL-212 is undergoing Phase III clinical trials for the management of chronic refractory gout. Selecta is also advancing potential treatments for a range of IgA-mediated conditions, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. Their gene therapy pipeline further includes SEL-313, a preclinical candidate targeting ornithine transcarbamylase deficiency, and SEL-399, which is designed to ascertain the optimal ImmTOR dosage for minimizing the formation of antibodies to AAV capsids. Additionally, they are developing gene therapies for conditions such as Pompe disease, Duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorders, and other autoimmune diseases. The company is also exploring tolerogenic therapies for primary biliary cholangitis and other autoimmune disorders. Selecta Biosciences, Inc. has established licensing and collaboration agreements with a diverse group of partners, including Takeda Pharmaceuticals USA, Inc., Swedish Orphan Biovitrum, Sarepta Therapeutics, Inc., Asklepios Biopharmaceutical, Inc., Massachusetts Institute of Technology, Shenyang Sunshine Pharmaceutical Co., Ltd., Ginkgo Bioworks Holdings, Inc., and IGAN Biosciences, Inc. Founded in 2007, Selecta Biosciences, Inc. is headquartered in Watertown, Massachusetts.

Key metrics

ETFs linked to SELB

Broad-market and Healthcare sector ETFs an investor holding Selecta Biosciences is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how SELB fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Selecta Biosciences?

Selecta Biosciences trades under the ticker SELB on NASDAQ.

Which exchange is SELB listed on?

SELB is listed on NASDAQ.

What sector does Selecta Biosciences operate in?

Selecta Biosciences is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze SELB in a portfolio?

PortView shows SELB's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.